Biologic therapies for severe pediatric asthma: efficacy, safety, and biomarker-guided selection [0.03%]
儿科严重哮喘的生物疗法：疗效、安全性和生物标志物指导的选择
Enrico Tondina,Alessia Claudia Codazzi,Riccardo Castorina et al.
Enrico Tondina et al.
Background: Severe pediatric asthma is a heterogeneous, high-burden disease marked by variable corticosteroid responsiveness, frequent exacerbations, and substantial impairment in quality of life. Advances in airway immun...
Feasibility in a homeopathy for seasonal allergic rhinitis RCT: importance of therapeutic relationship and organizational capacity [0.03%]
六臂随机对照试验中开展季节性过敏性鼻炎顺势疗法的可行性：良好的医患关系和组织能力的重要性
J Siewert,L Joschko,R Schleicher et al.
J Siewert et al.
Introduction: Seasonal allergic rhinitis (SAR) patients often use homeopathy for symptom relief. The HOMEOSAR trial, a randomized, placebo-controlled, triple-blind multicenter study, included a qualitative sub-study to as...
Case Series: Combination of dupilumab and omalizumab as a way to reduce dupilumab-associated adverse events in severe atopic dermatitis [0.03%]
病例系列：联合使用度普利尤单抗和奥马珠单抗以减少重度特应性皮炎患者接受度普利尤单抗治疗的不良反应
Daria S Fomina,Olga A Mukhina,Elizaveta L Sedova et al.
Daria S Fomina et al.
Dupilumab is a fully human monoclonal antibody directed against the interleukin-4 receptor subunit α, the common chain of the IL-4 and IL-13 receptors. Dupilumab has been demonstrated to be highly effective in the treatment of severe atopi...
Successful use of stapokibart as a biological therapy for allergic fungal rhinosinusitis: a case report [0.03%]
斯塔福巴汀治疗过敏性真菌性鼻窦炎的生物疗法应用效果良好：病例报告
Hua Cai,Xue-Jie Luo,Ya-Qi Cao et al.
Hua Cai et al.
Purpose: To present a rare, to our knowledge previously undescribed, case of successful AFRS management using stapokibart (CM310). Patients and methods: ...
Editorial: Novel and promising laboratory biomarkers for allergic disease diagnosis and prognosis: clinical applicability [0.03%]
论著：过敏性疾病诊断和预后的新颖且有前景的实验室生物标志物：临床适用性
Henry Velazquez-Soto,Xin Wang,María C Jiménez-Martínez
Henry Velazquez-Soto
Global airways: a Danish nationwide real-life registry of biologic therapy for chronic rhinosinusitis with nasal polyps [0.03%]
丹麦全国真实世界生物制剂治疗慢性鼻窦炎合并鼻息肉注册登记研究
Vibeke Backer,Kasper Aanæs,Bent Ivan Larsen et al.
Vibeke Backer et al.
Background: The relationship between chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP) and type 2 inflammation has led to the use of biologic treatment for uncontrolled cases. As biologic treatment remains a relativ...
Clinical and molecular aspects of managing chronic spontaneous urticaria: identifying endotypes, phenotypes, and determinants of treatment response and resistance [0.03%]
慢性自发性荨麻疹的诊疗现状及分子机制：识别发病内型、表型和治疗反应及耐药决定因素
Özlem Su Küçük,Muhammed Burak Yücel
Özlem Su Küçük
Chronic spontaneous urticaria (CSU) is a clinically heterogeneous, mast cell-driven inflammatory disease in which disease expression, treatment response, and resistance are determined by distinct but overlapping immunopathogenic mechanisms....
Katarina I Trapanotto,Mary F Lee-Wong,Robert A Promisloff et al.
Katarina I Trapanotto et al.
United States Pharmacopeia (USP), a nonprofit organization that sets safety standards for food, medicine and supplements updated its Chapter 797 standards for the preparation of allergy immunotherapy vials in November 2023. These guidelines...
Predictors of early treatment response to antihistamines and omalizumab in chronic spontaneous urticaria [0.03%]
抗组胺药和奥马珠单抗治疗慢性自发性荨麻疹早期反应的预测因素分析
P Calzari,E M Favale,M Cugno et al.
P Calzari et al.
Chronic spontaneous urticaria (CSU) is a common immune-mediated skin disorder characterized by spontaneous wheals, angioedema, or both, persisting for more than six weeks. Its pathogenesis is multifactorial, involving mast cell and basophil...
Carmen Panaitescu,Laura Haidar,Maria-Roxana Buzan et al.
Carmen Panaitescu et al.
The increasing availability of biologic therapies for allergic diseases has highlighted the need for more precise, mechanism-based patient selection. Traditional approaches based on disease phenotypes often fall short in predicting therapeu...